Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Overview 2024-2033 – Share, Size, Insights, Forecast

A cell and gene therapy contract development and manufacturing organization (CDMO) is a specialized company that provides services to support the development, manufacturing, and commercialization of cell-based and gene therapy products. These organizations offer services tailored to the unique needs of companies developing advanced therapies, including biopharmaceutical companies, academic institutions, and government agencies. Cell and gene therapy CDMOs play a critical role in accelerating the development and commercialization of advanced therapy products by offering specialized expertise, infrastructure, and services to support their clients' needs from early-stage development through commercialization. Sizing and Forecast The cell and gene therapy contract development and manufacturing organization (CDMO) market size has grown exponentially in recent years. It will grow from $4.24 billion in 2023 to $5.41 billion in 2024 at a compound annual growth rate (CAGR) of 27.7%.  The growth in the historic period can be attributed to increased technological advancements, favorable regulatory frameworks, increased investment, high prevalence of genetic disorders, and an increased number of strategic partnerships. The cell and gene therapy contract development and manufacturing organization (CDMO) market size is expected to see exponential growth in the next few years. It will grow to $14.52 billion in 2028 at a compound annual growth rate (CAGR) of 28.0%.  The growth in the forecast period can be attributed to expanded therapeutic applications, regulatory evolution, increased investment, technological innovations, and global collaboration. Major trends in the forecast period include increased demand for personalized therapies, growth in automation and digitalization, expansion of manufacturing capacities, emergence of novel delivery systems, and heightened focus on sustainability and environmental impact.  Order your report now for swift delivery, visit the link: https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-contract-development-and-manufacturing-organization-cdmo-global-market-report Segmentation & Regional Insights The cell and gene therapy contract development and manufacturing organization (CDMO) market covered in this report is segmented – 1) By Product Type: Gene Therapy, Gene-Modified Cell Therapy, Cell Therapy 2) By Phase: Phase 1, Phase 2, Phase 3, Phase 4 3) By Indication: Oncology, Infectious Diseases, Neurological Disorders, Rare Diseases, Other Indications North America was the largest region in the cell and gene therapy contract development and manufacturing organization (CDMO) market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell and gene therapy contract development and manufacturing organization (CDMO) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. Intrigued to explore the contents? Secure your hands-on a free sample copy of the report: https://www.thebusinessresearchcompany.com/sample.aspx?id=15753&type=smp Major Driver Impacting Market Growth The growing prevalence of cancer cases is expected to propel the growth of the cell and gene therapy contract development and manufacturing organization (CDMO) market going forward. Cancer is a group of diseases characterized by uncontrolled growth and spread of abnormal cells in the body. The growing prevalence of cancer cases is due to aging populations, lifestyle changes, environmental exposures, and improved detection methods. Cell and gene therapy contract development and manufacturing organization (CDMO) helps reduce cancer prevalence by developing and manufacturing innovative, targeted treatments that enhance efficacy and patient outcomes. For instance, in October 2022, according to Macmillan Cancer Support, a UK-based charitable organization, the estimated number of people living with cancer in the UK is projected to increase from 3 million in 2022  to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Therefore, the growing prevalence of cancer cases drives the growth of the cell and gene therapy contract development and manufacturing organization (CDMO) market. Key Industry Players Major companies operating in the cell and gene therapy contract development and manufacturing organization (CDMO) market are Pfizer Inc, Merck & Co. Inc., Thermo Fisher Scientific Inc, Novartis AG, FUJIFILM Diosynth Biotechnologies, AGC Biologics, Ajinomoto Co Inc, Lonza Group, Catalent Inc, Charles River Laboratories International Inc, Sartorius Stedim Biotech, Samsung Biologics Co Ltd, WuXi Biologics, Recipharm AB, Almac Group Ltd, KBI Biopharma, Rentschler Biopharma, Bio Elpida, Oxford BioMedica Plc, Avid Bioservices Inc, Cell and Gene Therapy Catapult, VGXI Inc, Genezen Laboratories Inc., Pluri Inc., OmniaBio Inc.  The cell and gene